TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers

CAMBRIDGE, Mass., Sept. 15, 2017 /PRNewswire/ -- TCR² Therapeutics Inc. today announced that it has been named one of the "Top 15 Innovative Immuno-Oncology Biotechs to Watch in 2018" by Immuno-Oncology (IO) Frontiers. The list of honorees represents emerging players in the immunotherapy field with disruptive technologies that can transform the future treatment of cancer. Garry Menzel, Ph.D., Chief Executive Officer, will give an oral presentation highlighting the company's technology and lead programs at the IO Frontiers conference to be held on September 20-21 in Berlin, Germany.

"We are honored to be recognized for the successful progress of our unique approach to battling solid tumors," said Dr. Menzel. "Our TRuC™-T cell platform represents a novel class of engineered T cell technology that engages the entire T cell receptor complex which we believe is critical for treating solid tumors. Using this approach, we have demonstrated superiority for our lead program TC-210 compared to CAR-T cells in preclinical studies and its potential to improve efficacy, safety and persistence in solid tumors. I look forward to sharing these data at this prestigious scientific forum."

TCR² Therapeutics Presentation at IO Frontiers

• Title: TRuC™-T Cells: A Novel Class of TCR-Based Therapies for Solid Tumors
• Session: New Targets and Innovative Ways to Induce a Better Immune Response
• Date & Time: Wednesday September 20, 2017 from 2:35pm-2:50pm CEST
• Location: Maritim proArte Hotel in Berlin, Germany
• Presenter: Garry Menzel, PhD, Chief Executive Officer

About TCR² Therapeutics
TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC™-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

SOURCE TCR2 Therapeutics

Related Links

http://www.tcr2.com